Lisocabtagene maraleucel (liso-cel) (Breyanzi, Bristol Myers Squibb) will emerge as the standard of care (SOC) for second-line therapy of relapsed-refractory large B-cell lymphoma (LBCL), according to results of a phase 3 clinical trial. The CD-19?targeted chimeric antigen receptor (CAR) T-cell therapy was approved only a year ago for use as a third-line therapy on the basis of the TRANSCEND trial, but this new study—called TRANSFORM—supports its use at an earlier stage.
“When